<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03821714</url>
  </required_header>
  <id_info>
    <org_study_id>2018ZDSYLL057-P01</org_study_id>
    <nct_id>NCT03821714</nct_id>
  </id_info>
  <brief_title>Effects of Glucocorticoid Combined With Vitamin C and Vitamin B1 on Microcirculation in Severe Septic Shock</brief_title>
  <official_title>Effects of Glucocorticoid Combined With Vitamin C and Vitamin B1 Versus Hydrocortisone Alone on Microcirculation in Severe Septic Shock</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Southeast University, China</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Southeast University, China</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aimed to investigate the effect of Glucocorticoid combined with vitamin C and&#xD;
      vitamin B1 versus hydrocortisone alone on microcirculation in septic shock patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This prospective, double-blind, randomized, controlled trial enrolled septic shock patients&#xD;
      admitted to the intensive care unite of a tertiary teaching hospital. We randomly assigned&#xD;
      the enrolled patients to the treatment group (hydrocortisone combined with vitamin C and&#xD;
      vitamin B1 added to standard care) and the control group (hydrocortisone alone added to&#xD;
      standard care) in a 1:1 ratio. The primary outcome was perfusion vascular density (PVD) at 24&#xD;
      hours after treatment. We used the sublingual microcirculation imaging system to monitor PVD.&#xD;
      We further validated the primary outcome by observing differences in renal perfusion&#xD;
      monitored by renal contrast-enhanced ultrasound (CEUS) between the treatment group and the&#xD;
      control group.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 1, 2019</start_date>
  <completion_date type="Actual">January 30, 2020</completion_date>
  <primary_completion_date type="Actual">January 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Perfused vessel density (PVD)</measure>
    <time_frame>24 hours after treatment</time_frame>
    <description>Determinant of capillary diffusive capacity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>proportion of perfusion vessels</measure>
    <time_frame>24 hours after treatment</time_frame>
    <description>sublingual microcirculation parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>total vascular density</measure>
    <time_frame>24 hours after treatment</time_frame>
    <description>sublingual microcirculation parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>microvascular flow index</measure>
    <time_frame>24 hours after treatment</time_frame>
    <description>sublingual microcirculation parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>renal contrast-enhanced ultrasound parameters</measure>
    <time_frame>24 hours after treatment</time_frame>
    <description>renal perfusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>lactate</measure>
    <time_frame>24 hours after treatment</time_frame>
    <description>Tissue perfusion parameter</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Septic Shock</condition>
  <arm_group>
    <arm_group_label>Glucocorticoid combination therapy Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hydrocortisone 200mg continuous intravenous infusion(24h) combined with vitamin C1.5g intravenous infusion every 6 hours and vitamin B1 200mg intravenous infusion every 12 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glucocorticoid Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Hydrocortisone 200mg continuous intravenous infusion(24h)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glucocorticoid combination therapy</intervention_name>
    <description>Glucocorticoid combination therapy is defined as the combination of hydrocortisone, vitamin C, and vitamin B1.</description>
    <arm_group_label>Glucocorticoid combination therapy Group</arm_group_label>
    <other_name>Hydrocortisone, vitamin C and vitamin B1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glucocorticoid</intervention_name>
    <description>The glucocorticoid group was defined as the use of hydrocortisone alone.</description>
    <arm_group_label>Glucocorticoid Group</arm_group_label>
    <other_name>Hydrocortisone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Septic shock&#xD;
&#xD;
          2. A dose of norepinephrine (&gt;15ug/min)&#xD;
&#xD;
          3. Age ≥18 and ≤80 years old&#xD;
&#xD;
          4. Signing Informed Consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Meet the inclusion criteria for more than 12 hours&#xD;
&#xD;
          2. Clinician judges that corticosteroid therapy should not be used&#xD;
&#xD;
          3. Pregnant&#xD;
&#xD;
          4. Uncontrolled malignancy&#xD;
&#xD;
          5. Glucocorticoid therapy was used within seven days before admission.&#xD;
&#xD;
          6. Expected death within 24 hours&#xD;
&#xD;
          7. The sublingual microcirculation cannot be measured&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jingyuan Xu, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Southeast University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nanjing Zhongda Hospital, Southeast University</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>January 19, 2019</study_first_submitted>
  <study_first_submitted_qc>January 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 30, 2019</study_first_posted>
  <last_update_submitted>May 25, 2021</last_update_submitted>
  <last_update_submitted_qc>May 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Southeast University, China</investigator_affiliation>
    <investigator_full_name>Jingyuan,Xu</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>septic shock</keyword>
  <keyword>glucocorticoid</keyword>
  <keyword>vitamin C</keyword>
  <keyword>microcirculation</keyword>
  <keyword>Vitamin B1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock, Septic</mesh_term>
    <mesh_term>Shock</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Hydrocortisone</mesh_term>
    <mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
    <mesh_term>Hydrocortisone acetate</mesh_term>
    <mesh_term>Hydrocortisone hemisuccinate</mesh_term>
    <mesh_term>Glucocorticoids</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

